Prophylaxis Of Infectious Complications With Colony-Stimulating Factors In Adult Cancer Patients Undergoing Chemotherapy – Evidence-based Guidelines From the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO)

This clinical practice guideline examines the effects of G-CSF, pegfilgrastim, and biosimilar XM02 on the primary and secondary prevention of infection in adult patients with haematological malignancies or solid tumours who are undergoing chemotherapy. Considerations are made to patient age, patient risk for febrile neutropenia (FN), and timing of treatment. Comparisons are made between pegfilgrastim and filgrastim, and pegfilgrastim and placebo and primary outcome of interest is incidence of febrile neutropenia (FN).